Pharmaceutical Benefits Advisory Committee (PBAC)

Australia’s HTA and reimbursement advisory body for PBS listing decisions, including esketamine (Spravato) assessment materials.

Reimbursement & Market Access Snapshot

Health Economists

Service Model

Public Payer / National Coverage Authority

Jurisdiction

National

Coverage

1 country

Last Verified

Apr 8, 2026

Focus Areas

HTA Evidence AppraisalCost-Effectiveness ModelingBudget Impact AnalysisCoverage Policy DesignFormulary & Access Criteria

Evidence Requirements

Clinical Efficacy EndpointsComparative EffectivenessCost-EffectivenessBudget ImpactPatient-Reported Outcomes

Market Access Notes

PBAC forms recommendations underpinning PBS listing decisions and publishes medicine-status updates that include esketamine-related records.

Verification

Verified

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement Status

Active

Source Evidence

PBS - PBAC Meetings and Outcomes

https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings

PBS Medicine Status Document - Esketamine

https://www.pbs.gov.au/medicinestatus/document/1195.html